The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour

被引:24
作者
de Boer, Stefanie Amarens [1 ,2 ]
Lefrandt, Joop Daniel [2 ]
Petersen, Japke Frida [1 ,2 ]
Boersma, Hendrikus Hessel [3 ]
Mulder, Douwe Johannes [2 ]
Hoogenberg, Klaas [1 ]
机构
[1] Martini Hosp, Dept Internal Med, Groningen, Netherlands
[2] Univ Groningen, Dept Vasc Med, Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
关键词
Diabetes mellitus; Eating behaviour; GLP-1 receptor agonist; Insulin therapy; Weight loss; GLUCAGON-LIKE PEPTIDE-1; GLYCEMIC CONTROL; EXENATIDE TWICE; LIRAGLUTIDE; THERAPY; WEIGHT;
D O I
10.1007/s11096-015-0219-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate GLP-1 RA treatment on body weight, glycaemic control and total daily insulin dose in obese, insulin-using type 2 diabetes patients after 2 years follow-up in a real life setting and to explore a possible relation with eating behaviour. Setting The Martini Hospital and the University Medical Center in Groningen in the Netherlands. Methods Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2 years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose. Results 151 Patients started with exenatide or liraglutide. 120 patients completed the 2 years follow-up. From baseline to 2 years, body weight (mean +/- A SD) changed from 117.9 +/- A 22.1 to 107.9 +/- A 22.9 kg (P < 0.0001), HbA1c (median, IQR) changed from 7.9 (7.2-8.9) to 7.6 (6.9-8.3) % [63 (55-74) to 60 (52-67) mmol/mol] (P < 0.0001), total daily insulin dose changed from 90 (56-150) to 60 (0-100) Units/day (P < 0.0001). Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (-3.1 %) and restrained (n = 41) in the greatest (-10.3 %) in comparison with emotional (n = 37, -8.5 %) and indifferent (n = 25, -9.6 %) eating behaviours. Conclusion Two year of GLP-1 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in obese, insulin-using type 2 diabetes patients in a real life setting. Largest weight loss was achieved in patients with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction.
引用
收藏
页码:144 / 151
页数:8
相关论文
共 23 条
[1]   Relationship between eating styles and temperament in an Anorexia Nervosa, Healthy Control, and Morbid Obesity female sample [J].
Banos, Rosa M. ;
Cebolla, Ausias ;
Moragrega, Ines ;
Van Strien, Tatjana ;
Fernandez-Aranda, Fernando ;
Agueera, Zaida ;
de la Torre, Rafael ;
Casanueva, Felipe F. ;
Fernandez-Real, Jose M. ;
Fernandez-Garcia, Jose C. ;
Fruhbeck, Gema ;
Gomez-Ambrosi, Javier ;
Jimenez-Murcia, Susana ;
Rodriguez, Roser ;
Tinahones, Francisco J. ;
Botella, Cristina .
APPETITE, 2014, 76 :76-83
[2]   Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].
Buse, John B. ;
Rosenstock, Julio ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Brett, Jason H. ;
Zychma, Marcin ;
Blonde, Lawrence .
LANCET, 2009, 374 (9683) :39-47
[3]   Risk Factors for Adult Overweight and Obesity in the Quebec Family Study: Have We Been Barking Up the Wrong Tree? [J].
Chaput, Jean-Philippe ;
Leblanc, Claude ;
Perusse, Louis ;
Despres, Jean-Pierre ;
Bouchard, Claude ;
Tremblay, Angelo .
OBESITY, 2009, 17 (10) :1964-1970
[4]   Preliminary Examination of Glucagon-Like Peptide-1 Levels in Women with Purging Disorder and Bulimia Nervosa [J].
Dossat, Amanda M. ;
Bodell, Lindsay P. ;
Williams, Diana L. ;
Eckel, Lisa A. ;
Keel, Pamela K. .
INTERNATIONAL JOURNAL OF EATING DISORDERS, 2015, 48 (02) :199-205
[5]   The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].
Drucker, Daniel J. ;
Nauck, Michael A. .
LANCET, 2006, 368 (9548) :1696-1705
[6]   Glucagon-like peptide-1 receptor agonist and basal insulin combination tre atment for the management of type 2 diabetes: a systematic review and meta-analysis [J].
Eng, Conrad ;
Kramer, Caroline K. ;
Zinman, Bernard ;
Retnakaran, Ravi .
LANCET, 2014, 384 (9961) :2228-2234
[7]   Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes [J].
Fujishima, Yuya ;
Maeda, Norikazu ;
Inoue, Kana ;
Kashine, Susumu ;
Nishizawa, Hitoshi ;
Hirata, Ayumu ;
Kozawa, Junji ;
Yasuda, Tetsuyuki ;
Okita, Kohei ;
Imagawa, Akihisa ;
Funahashi, Tohru ;
Shimomura, Iichiro .
CARDIOVASCULAR DIABETOLOGY, 2012, 11
[8]   Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review [J].
Goldenberg, Ronald .
CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (03) :431-445
[9]   External cues in the control of food intake in humans: The sensory-normative distinction [J].
Herman, C. P. ;
Polivy, J. .
PHYSIOLOGY & BEHAVIOR, 2008, 94 (05) :722-728
[10]   ANXIETY, RESTRAINT, AND EATING BEHAVIOR [J].
HERMAN, CP ;
POLIVY, J .
JOURNAL OF ABNORMAL PSYCHOLOGY, 1975, 84 (06) :666-672